Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment

Circulation

Volumn 103, Issue 6, 2001, Pages 792-798

  Zambon, Alberto ^a   Deeb, Samir S ^a   Brown, B Greg ^a   Hokanson, John E ^a   Brunzell, John D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Coronary artery disease; Genes; Lipoproteins; Liver; Pharmacogenetics

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN; LIVER TRIACYLGLYCEROL LIPASE; LOW DENSITY LIPOPROTEIN;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY ARTERY OBSTRUCTION; DENSITY GRADIENT CENTRIFUGATION; DISEASE ASSOCIATION; DYSLIPIDEMIA; ENZYME ACTIVITY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; LIPOPROTEIN METABOLISM; MALE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROMOTER REGION; REMISSION;

EID: 0035852726     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.103.6.792     Document Type: Article

References (29)

1. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
2. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS/TexCAPS
3. Randomized trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
4. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
5. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study
6. Relationship between plasma LDL concentrations during treatment with pravastatin and recurrent coronary events in the cholesterol and recurrent events trial
7. Effect of hepatic lipase on LDL in normal men and those with coronary artery disease
8. Determinants of LDL subfraction distribution and concentrations in young normolipidemic subjects
9. 2 in man
10. Low-density lipoprotein subclass patterns and risk of myocardial infarction
11. Small dense low-density lipoprotein particles as predictor of the risk of ischemic heart disease in men
12. A hepatic lipase (LIPC) allele associated with high plasma concentrations of high-density lipoprotein cholesterol
13. Common C-to-T substitution at position -480 of the hepatic lipase promoter associated with a lowered lipase activity in coronary artery disease patients
14. Hepatic lipase gene polymorphism influence plasma HDL levels: Results from the Finnish EARS participants. European Atherosclerosis Research
15. Association of variation in hepatic lipase activity with promoter variation in hepatic lipase gene
16. 2 cholesterol
17. Hepatic lipase activity is lower in African American men than in white American men: Effects of the 5′ flanking polymorphism in the hepatic lipase gene (LIPC)
18. Hepatic lipase: New insights from genetic and metabolic studies
19. Predominance of dense low-density lipoprotein particles predicts angiographic benefit of therapy in the Stanford Coronary Risk Intervention Project
20. Evidence for a new pathophysiological mechanism for coronary artery disease regression: Hepatic lipase-mediated changes in LDL density
21. Regression of coronary artery disease as a result of intensive lipid lowering therapy in men with high levels of apoiipoprotein B
22. Single vertical spin density gradient ultracentrifugation
23. Human adipose tissue lipoprotein lipase: Changes with feeding in relation to postheparin plasma enzyme
24. The C-514T polymorphism in the human hepatic lipase gene promoter diminishes its activity
25. Association of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis
26. Enhanced susceptibility to in vitro oxidation of the dense low density lipoprotein subfraction in healthy subjects
27. Atherosclerosis An inflammatory disease
28. Apolipoprotein-mediated removal of cellular cholesterol and phospholipids
29. Progression of coronary artery disease predicts clinical coronary events: Long-term follow-up from the cholesterol lowering atherosclerosis study